The University of Texas MD Anderson Cancer Center today announced the signing of an agreement with the International Atomic Energy Agency (IAEA) to become an IAEA Collaborating Centre. Working together, MD Anderson and the IAEA aim to enhance radiation oncology, radiation physics, radiology, nuclear medicine and nutrition globally. MD Anderson operates the most comprehensive radiation oncology facility in the world and will be the...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Women in low-income areas of the U.S. face a stark rise in cervical cancer incidence and mortality, according to a new study led by researchers...
Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.
Published today in Nature Medicine, the findings reveal an overall response (OR) rate of 48.6% at 100 days post treatment...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Vaccine demonstrates potential in delaying relapse of KRAS-mutated pancreatic and colorectal cancers
A vaccine showed potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone...